← Human Trials & Peer-Reviewed Studies
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial
Plain-language guide to PMID 22933438 (2012): parallel-group randomized controlled trial study of Insulin Aspart.
Key Facts
- PMID
- 22933438
- Journal
- Diabetes care
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Hirsch IB et al. (9 authors)
- DOI
- 10.2337/dc11-2503
- Registered trial
- NCT00978627
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin Aspart, published as a randomized controlled trial.
How the Study Was Run
The design is described as randomized and parallel-group.
The participants were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.
The Insulin Aspart group and the comparison group ran side by side rather than switching.
What Was Measured
Topics PubMed links to this paper include Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin Aspart, Insulin, Long-Acting and Meals.
What This Means in Plain Language
The paper is a randomized and parallel-group study of Insulin Aspart.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2012 (Diabetes care), a journal based in United States.
More context: the Insulin Aspart compound page, all human trials.
Our Notes on the Compound
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.